vimarsana.com

Page 27 - எழுந்திரு காடு பள்ளி ஆஃப் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Majoring in Marijuana--AcademicInfluence com Explores the Growing Trends in Cannabis in College and Career

The Emperor Wears No Clothes: A History of Cannabis/Hemp/Marijuana by Jack Herer The War We Never Fought by Peter Hitchens The Hasheesh Eater by Fitz Hugh Ludlow As legal restrictions fall like dominoes and legal production skyrockets, the momentum marijuana has in the United States ensures its future as an important area of study and business, says Dave Tomar, author of the article, and the managing editor of Inflection. Students interested in building a career in a budding field have a new option to consider. In keeping with our mission, we re here to help point them to the field s most influential institutions, people, and resources to help them achieve their educational and career goals.

Pegloticase Safe for Dialysis Patients With Gout

Gout treatment with pegloticase was well tolerated in a dialysis-dependent population, researchers found in a small study. In an analysis of 42 patients with uncontrolled gout currently undergoing routine outpatient dialysis, most received on-label pegloticase (Krystexxa) consisting of biweekly infusions, with a median of three infusions, reported Anthony Bleyer, MD, of Wake Forest School of Medicine in Winston-Salem, North Carolina, and colleagues. In total, nine patients (21%) received 12 or more pegloticase infusions, and the median interval between doses was 14 days (average of 19.5 days). The findings were presented as a poster at the virtual National Kidney Foundation Spring Clinical Meeting. To date, we have limited literature around the use of pegloticase in chronic kidney disease patients receiving dialysis, though we know that people with chronic kidney disease are more likely to develop gout, Bleyer explained to

Clinical Trials in COVID Era: How To Keep Moving Forward

07 Apr 2021 Part 2 of a two-part story. Click here for Part 1. The COVID-19 pandemic has touched every aspect of health, from neurologic disease broadly (see Part 1 of this story) to clinical research. At the 15th International Conference on Alzheimer s and Parkinson s Diseases, held virtually March 9–14, clinical investigators talked about how they tried to prevail despite interruptions and preserve their trials. Looking to the future, how they will handle people who had COVID-19, or develop it during a trial, remains unclear. Home nursing allowed dosing to continue in Roche s gantenerumab trials. Other trials used telemedicine to continue recruitment and interventions. How will researchers include people who had COVID in clinical trials?

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.